Skip to main content
Clinical Trials/NCT03521804
NCT03521804
Terminated
N/A

A Single-Arm Study to Assess the Safety and Efficacy of the SoundBite™ Crossing System With ACTIVE Wire in Coronary Chronic Total Occlusions (the ACTIVE Trial).

SoundBite Medical Solutions, Inc.5 sites in 2 countries35 target enrollmentJune 21, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic Total Occlusion of Coronary Artery
Sponsor
SoundBite Medical Solutions, Inc.
Enrollment
35
Locations
5
Primary Endpoint
Device success
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The objective of this study is to evaluate the safety and efficacy of the SoundBite™ Crossing System - Coronary (SCS-C) in a subject population with chronic coronary artery disease including Chronic Total Occlusion (CTO).

Detailed Description

The study is intended to demonstrate that the SoundBite™ Crossing System - Coronary can facilitate the passage of either 1) devices intended to treat a CTO or 2) guidewires or additional crossing devices into the true lumen distal to the CTO. SoundBite™ Crossing System - Coronary, which consists of a re-usable console and a disposable device (ACTIVE Wire). The SoundBite™ Crossing System - Coronary is intended to facilitate passage of a guidewire or therapeutic devices through a coronary artery Chronic Total Occlusion. This is a prospective, multi-center, multinational, single-arm, phased clinical study intended to provide pivotal data for device approval.

Registry
clinicaltrials.gov
Start Date
June 21, 2018
End Date
November 20, 2020
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
SoundBite Medical Solutions, Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Device success

Time Frame: Day 1

Device Success defined as: Successful antegrade crossing of the CTO into the true arterial lumen distal to the occlusion following advancement of at least 3 mm of the Soundbite(TM) Crossing System into any segment as assessed by the core angiographic laboratory. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (e.g. Stingray); absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.

Freedom from the composite SoundBite™ Crossing System related MAEs

Time Frame: 48 hours or until discharge

Freedom from the composite SoundBite™ Crossing System related major adverse events (MAEs) at 48 hours or hospital discharge (whichever occurs first) post procedure, as per Clinical Events Committee (CEC) adjudication, defined as: * Cardiovascular related deaths * Myocardial Infarction (Primary definition of clinically relevant post procedure MI from SCAI (1). * Coronary Artery Perforation requiring treatment * Unscheduled cardiac surgery anytime between enrollment to completion of the study. * Intra-procedure stroke * Radiation exposure ≥ 8 Gy

Secondary Outcomes

  • Overall Device Success(Day 1)
  • Procedural Success(Day 1)
  • Freedom from SoundBite™ Crossing System related MAE(30 days post-procedure)
  • Technical Success(Day 1)
  • Clinical Success:(30 days post-procedure)

Study Sites (5)

Loading locations...

Similar Trials